Loading
A phase 1/2 trial of CR-002 run by Crescent Biopharma, Inc., now recruiting.
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07909031 by Crescent Biopharma, Inc., with 219 participants planned, started 2026-10-21. Conditions recorded: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic and Non-small Cell Lung Cancer (NSCLC). Interventions recorded: CR-002.
Shares Oesophageal squamous cell carcinoma, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Gastric & gastro-oesophageal junction cancer, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Crescent Biopharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/